INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 222 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $6,728,873 | -32.0% | 501,033 | -37.4% | 0.12% | -36.9% |
| Q4 2022 | $9,896,000 | -11.3% | 800,000 | 0.0% | 0.20% | -11.4% |
| Q3 2022 | $11,160,000 | +1.0% | 800,000 | 0.0% | 0.22% | -6.8% |
| Q2 2022 | $11,048,000 | -15.1% | 800,000 | 0.0% | 0.24% | +15.7% |
| Q1 2022 | $13,016,000 | +144.0% | 800,000 | +144.3% | 0.20% | +200.0% |
| Q4 2021 | $5,334,000 | -57.0% | 327,444 | +227.4% | 0.07% | -80.5% |
| Q4 2019 | $12,392,000 | -46.0% | 100,000 | -51.2% | 0.35% | -55.8% |
| Q1 2019 | $22,931,000 | +35.4% | 205,000 | +22.0% | 0.79% | +5.2% |
| Q4 2018 | $16,933,000 | – | 168,000 | – | 0.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |